TScan Therapeutics

TCRX48

$5.55arrow_drop_down1.42%-$0.08

TCRX48

$5.55

arrow_drop_down1.42%-$0.08

Performance History

Key Stats
Open	$5.62
Prev. Close	$5.63
EPS	-0.65
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	5.47	5.72
52 Week Range	2.35	9.69

Ratios







EPS	-0.65

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About TScan Therapeutics (TCRX)

TScan Therapeutics, Inc. (TCRX) is a biotechnology company that specializes in the development of T-cell receptor (TCR) therapeutics to treat cancer. The company's stock, TCRX, has a price history that reflects its journey in the market. Starting at its initial public offering (IPO) price, TCRX has seen fluctuations over the years, influenced by various factors such as company news, market trends, and investor sentiment.

As of the latest quote, TCRX is trading at $X per share. This represents the current value of the stock in the market. Investors and market participants can track TCRX's performance through real-time quotes and monitor any changes that may occur. This information allows for informed decision-making and helps investors stay updated on the stock's movement.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Gavin MacBeath Ph.D.
Headquarters: Waltham
Employees: 135
Exchange: NASDAQ

Keep an eye on TScan Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is TScan Therapeutics's (TCRX) price per share?

The current price per share for TScan Therapeutics (TCRX) is $5.55. The stock has seen a price change of -$0.08 recently, indicating a -1.42% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for TScan Therapeutics (TCRX)?

For TScan Therapeutics (TCRX), the 52-week high is $9.69, which is 74.59% from the current price. The 52-week low is $2.35, the current price is 136.17% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is TScan Therapeutics (TCRX) a growth stock?

TScan Therapeutics (TCRX) has shown an average price growth of 0.41% over the past three years. It has received a score of 95 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying TScan Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is TScan Therapeutics (TCRX) stock price performance year to date (YTD)?

As of the latest data, TScan Therapeutics (TCRX) has a year-to-date price change of -2.8%. Over the past month, the stock has experienced a price change of -6.57%. Over the last three months, the change has been -35.91%. Over the past six months, the figure is -22.38%.

help

Is TScan Therapeutics (TCRX) a profitable company?

TScan Therapeutics (TCRX) has a net income of -$89.22M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 74.53% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -6.36K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $21.05M, with a revenue growth rate of 55.52%, providing insight into the company's sales performance and growth. The gross profit is $15.69M. Operating income is noted at -$93.46M. Furthermore, the EBITDA is -$106.66M.

help

What is the market capitalization of TScan Therapeutics (TCRX)?

TScan Therapeutics (TCRX) has a market capitalization of $294.01M. The average daily trading volume is 246.62K, indicating the stock's liquidity and investor engagement.